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This study investigated the relationship between white matter hyperintensities (WMH) and 
cerebrospinal fluid (CSF) Alzheimer’s disease (AD) biomarkers. Subjects included 180 controls, 
107 individuals with a significant memory concern (SMC), 320 individuals with early mild 
cognitive impairment (EMCI), 171 individuals with late mild cognitive impairment (LMCI) and 
151 individuals with AD, with 3T MRI and CSF Aβ1-42, total tau (t-tau) and phosphorylated tau 
(p-tau) data. Multiple linear regression models assessed the relationship between WMH and CSF 
Aβ1-42, t-tau and p-tau. Directionally, a higher WMH burden was associated with lower CSF 
Aβ1-42 within each diagnostic group, with no evidence for a difference in the slope of the 
association across diagnostic groups (p=0.4). Pooling all participants, this association was 
statistically significant after adjustment for t-tau, p-tau, age, diagnostic group and APOE-ε4 status 
(p<0.001). Age was the strongest predictor of WMH (partial R2~16%) compared with CSF Aβ1-
42 (partial R2~5%). There was no evidence for an association with WMH and either t-tau or p-tau. 
This data is supportive of a link between amyloid burden and presumed vascular pathology. 
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The co-existence of cerebrovascular disease (CVD) and Alzheimer’s disease (AD) is increasingly 
well recognised; AD patients often display both AD pathology and underlying vascular 
pathologies at autopsy such as small vessel disease (SVD), microvascular injury and 
cerebrovascular lesions (Brayne et al., 2009, Esiri et al., 2014, Jellinger and Attems, 2006, Kapasi 
et al., 2017, Schneider et al., 2007, Schneider et al., 2009). Cerebrovascular pathology is well 
established as an important contributor to cognitive decline, acting as the primary cause of at least 
20% of dementias (Gorelick et al., 2011).  However, the relationship between CVD and the 
hallmark Alzheimer’s pathologies including tau and amyloid beta (Aβ) is yet to be fully 
characterised. 
Aβ deposition in the brain can be globally measured in vivo by analysing cerebrospinal fluid (CSF) 
levels of Aβ1-42, whereby an increase in parenchymal Aβ is signified by a decrease in CSF Aβ1-
42 (Blennow et al., 2010). Cerebral tau levels can also be assessed using CSF analysis, with the 
levels of total tau (t-tau) and phosphorylated tau (p-tau) thought to indicate neuronal damage and 
pathological tau deposition respectively (Jack et al., 2018). Markers of CVD are visible and 
quantifiable on magnetic resonance imaging (MRI), with perhaps the best characterised being 
white matter hyperintensities (WMH) that appear hyperintense on T2-weighted or FLAIR imaging 
and hypointense on T1-weighted imaging (Wardlaw et al., 2013). WMH have numerous 
histopathological correlates, including ependymal loss, cerebral ischemia and demyelination 
(Gouw et al., 2011). However, it may be that WMH are not only a marker of CVD, but also occur 
as a result of Alzheimer’s pathologies (McAleese et al., 2015, McAleese et al., 2017).   
Research studies are now moving towards a more biomarker led approach to AD (Jack et al., 2018), 
making it important to understand how possible biomarkers are interrelated at different stages of 
disease. Although no cerebrovascular biomarkers have been included in the research framework 
proposed by Jack et al. (2018), WMH are a good candidate marker to enhance our understanding 
of the associations between AD and vascular pathology.  
WMH have shown associations with amyloid accumulation, as measured by positron emission 
tomography (Kandel et al., 2016, Marnane et al., 2016) and CSF biomarkers (Marnane et al., 2016, 
Pietroboni et al., 2018). Tau aggregation has also been linked to WMH burden (McAleese et al., 
2015, Tosto et al., 2015), although results are somewhat less consistent (Kester et al., 2014, Osborn 
et al., 2018). The aim of this study was to add evidence to further characterise these complex 
relationships between AD and vascular biomarkers, and to extend the current literature by 
examining these relationships across the full spectrum from normal ageing to AD. We used 
continuous as opposed to binary measures of AD biomarkers, to more sensitively examine 
relationships with WMH. To the best of our knowledge, this study is the first to look at 
relationships between traditional biomarkers of AD (CSF Aβ1-42, t-tau and p-tau) and WMH in 
controls, individuals with a significant memory concern (SMC), individuals with early MCI 
(EMCI), individuals with late MCI (LMCI) and individuals with AD. We hypothesise that WMH 
will show associations with CSF Aβ1-42, t-tau and p-tau biomarkers, reflecting the potential 
relationships between vascular dysfunction, amyloid deposition, neurodegeneration and tau 
deposition. Since WMH are likely to represent different admixtures of pathology at different 
disease stages, with recent evidence suggesting in later disease stages WMH associations with tau 
may be stronger (McAleese et al., 2017) and Aβ1-42 may be weaker (Zhou et al., 2009), we also 
hypothesise that the relationships between Aβ and tau biomarkers and WMH may change 
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throughout the disease course with stronger associations between tau markers and WMH at later 
disease stages, and weaker associations between Aβ1-42 and WMH at the more advanced stages. 
2. Materials and methods 
 
2.1 Cohort:  
The demographic, imaging and biological data used for this study were downloaded from the 
ADNI database (http://adni.loni.usc.edu/). Both ADNIGO and ADNI2 data were used. ADNI is a 
multicentre, longitudinal public-private funded partnership, with the primary goal of using 
demographic, biomarker, neuropsychological and MRI data to monitor progression of AD. Since 
2003, Principle Investigator Michael W. Weiner, MD, has overseen recruitment of healthy 
controls, MCI and AD subjects from over 60 sites across the United States and Canada. (For up-
to-date information, see www.adni-info.org). 
Ethical approval was obtained by the Institutional Review Board at each participating centre. All 
study participants provided written informed consent. Participants took part in baseline and follow-
up clinical, neuropsychometric and MRI assessments. CSF data were collected from all subjects 
where possible.  
Five diagnostic groups were used for this study: Control, SMC, early MCI, late MCI and AD. A 
diagnosis of MCI was based on a significant memory concern (by participant or informant) and a 
clinical dementia rating of 0.5, but a Mini-Mental State Exam (MMSE) no lower than 24. Level 
of MCI (early or late) was determined by the Wechsler Memory Scale Logical Memory II. The 
SMC group was developed by ADNI to bridge the gap between controls and MCI participants, 
and is characterised by individuals who have self-reported a memory complaint but score within a 
normal range for cognition.  
2.2 CSF measurements 
 
CSF Aβ1-42, t-tau and p-tau were measured at the ADNI biomarker core (University of 
Pennsylvania) using the micro-bead-based multiplex immunoassay, the INNO-BIA AlzBio3 RUO 
test (Fujirebio, Ghent, Belgium), on the Luminex platform (Luminex Corp, Austin, Tx, USA). 
Raw, untransformed CSF values were used for all analyses. 
 
Additional analyses were carried out on CSF data obtained using the Roche Elecsys cobas e 601 
fully automated immunoassay platform at the ADNI biomarker core (University of Pennsylvania).  
 
2.3 Images and image processing:  
MRI (3T) were acquired across sites using a standardised protocol that was validated across 
platforms and described in Jack (2015). Images underwent quality control at the Mayo Clinic 
(Rochester, MN) which included assessments for protocol compliance and image quality, as well 
as checks for any significant neurological/radiological abnormalities. Baseline T1-weighted and 
FLAIR images from newly recruited individuals (i.e. with a first visit in ADNI2 or GO) were 
downloaded from the ADNI database. 
Bayesian Model Selection (BaMoS), a fully automated lesion segmentation pipeline, was applied 
to the co-registered image pairs (T1 and FLAIR) (Sudre et al., 2015). Briefly, BaMoS uses a 
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Gaussian mixture model to jointly model healthy tissue and unexpected intensity observations for 
the different anatomical brain tissue. The number of Gaussian components required to 
appropriately model each tissue type is dynamically optimised using a split and merge strategy. 
After fitting the model, candidate hyperintense WMH voxels are selected and the formed 
connected components classified as lesion or artefacts in a post-processing step based on anatomy 
rules. The resultant probability map of WMH was integrated to calculate the WMH volume. Only 
supratentorial WMH were included which were located in the white matter and subcortical grey 
matter. Total intracranial volumes (TIV) were calculated using the Geodesic information flows 
(GIF) label fusion framework, using T1-weighted images only (Cardoso et al., 2015). 
 
All automated WMH segmentations were visually inspected by a single rater who had been trained 
to segment WMH manually. The post-processing stage of the lesion classification was iteratively 
improved so as to limit the number of unusable segmentations and improve segmentations where 
large sections of lesion had been excluded. 22 cases were improved in this way and re-checked by 
a single rater, 21 of which were useable. Altogether, 12 regions were considered unusable out of 
944 regions in separate individuals. 3 further individuals were excluded due to lack of 
demographic/diagnostic information. 
To calculate the parietal and non-parietal WMH, Euclidean distance maps from the cortical lobar 
parcellation obtained from GIF were used to assign each WM voxel to the closest associated 
lobe.  
 
2.4 Statistical analyses:  
All statistical analysis was performed using STATA v13 (Stata Corp.). For WMH, most analyses 
were performed on loge transformed values to reduce skewness. To estimate differences in means 
across groups for demographic, imaging and CSF variables, linear regression models were used 
for continuous variables. For logeWMH, linear regression models were used with group as the 
predictor of interest and adjustment for TIV. We also present untransformed WMH volumes and 
again test for differences in these across diagnostic groups, using linear regression with adjustment 
for TIV.  
 
For analyses involving associations between WMH volume and CSF biomarkers, CSF biomarker 
values were standardised using the pooled within-group standard deviations (SDs) calculated from 
a linear regression model for each biomarker that allowed for differences in mean levels by group. 
Since WMH volumes were analysed on a logarithmic scale the resulting coefficients were back-
transformed so that they expressed percentage increases or decreases in WMH for each 1SD 
increase in CSF biomarkers. 
In order to explore whether CSF Aβ1-42 was associated with WMH across diagnostic groups, 
separate diagnostic group-specific linear regression models were fitted with logeWMH as the 
dependent variable and standardised Aβ1-42 and TIV as predictors. Between-group differences in 
slope were assessed by fitting a further model in the combined diagnostic groups, with interactions 
between diagnostic group and Aβ1-42, and carrying out a joint interaction test. All models were 
also refitted with age at baseline as an additional covariate. Analyses including age were 
secondary, since age at baseline may be on the causal pathway (theoretically a proxy for the 
number of vascular events that may have happened to an individual and the ability to clear 
amyloid). Analogous procedures were used with Aβ1-42 values being replaced by t-tau and then 
by p-tau.  
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Scatter plots of logeWMH volume against CSF Aβ1-42, t-tau or p-tau in each group were also 
generated to show unadjusted associations.  
We decided that should the joint interaction terms between participant group and Aβ1-42 in the 
above models not be statistically significant then any further analysis would be carried out in the 
cohort as a whole, adjusting for participant group but without including the interaction terms. In a 
first set of linear regression models we explored the Aβ1-42-WMH relationship adjusting for: i) 
nothing ii) TIV; iii) TIV and diagnostic group; iv) TIV, group and age; v) TIV, group age and 
APOE-ε4 status. This was repeated in a second set of models adding t-tau as a covariate to all 
models in the set i) to v) and in a third set of models by adding p-tau to all models in the set i) to 
v).  Partial R2 values for these potential confounders were also calculated for each covariate from 
model v) in each set. 
Supplementary analyses were also performed assessing the relationship between age and WMH 
using linear regression models with logeWMH being the dependent variable and age and TIV being 
predictors. This was initially performed in each diagnostic group separately, with one further 
model fitted that allowed for an interaction between diagnostic group and age. To assess the impact 
of vascular risk factors on the WMH-age relationship, smoking, hypertension, BMI and diabetes 
were added as covariates into separate diagnostic group-specific models and then in a combined 
model. To examine relationships between age and CSF variables, linear regression models were 
initially performed with Aβ1-42 as the dependent variable and age as the predictor, before 
replacing Aβ1-42 with t-tau and then p-tau. We also assessed associations between CSF 
biomarkers and parietal lobe WMH volumes vs. non-parietal WMH. These analyses used CSF 
Aβ1-42, t-tau or p-tau as the dependent variable and loge transformed parietal and non-parietal 
WMH volumes as predictor variables. The main analyses were repeated using the Elecsys 
biomarker data. These included the group-specific linear regression models with logeWMH as the 
dependent variable and standardised biomarker and TIV as predictors, and the analysis of CSF 















3.1 Group demographics 
 
Table 1: Demographic, imaging and CSF summary statistics 
Values are mean (SD) unless reported.  
Key: SMC, significant memory concern; EMCI, early mild cognitive impairment; LMCI, late mild cognitive impairment; AD, Alzheimer’s 
disease; MMSE, Mini Mental State Examination; TIV, total intracranial volume; WMH, white matter hyperintensities; BMI, body mass index 
a Adjusted for TIV 
b Available in 138 controls, 92 SMC, 252 EMCI, 144 LMCI, 119 AD 
 
There were 929 subjects with useable WMH values and available demographic. Table 1 shows 
demographic, imaging and CSF biomarker summary statistics for each diagnostic group. Between-
group differences were seen in age, with the AD group being the oldest and the early mild cognitive 
impairment (EMCI) group being the youngest. Participants differed as expected in terms of 
MMSE, APOE-ε4 status, WMH volume, CSF Aβ1-42, CSF t-tau and CSF p-tau with poorer 
scores, greater ε4 carriage and CSF biomarkers indicative of more pathology from controls to 
EMCI to late mild cognitive impairment (LMCI) to AD. In terms of vascular risk factors, 




N (total = 929) 180 107 320 171 151  
Age 73.4 (6.2) 72.3 (5.5) 71.0 (7.5) 72.4 (7.7) 75.0 (8.0) <0.001 
Male (%) 46 43 54 56 56  0.08 
MMSE /30 29.0 (1.3) 29.0 (1.3) 28.3 (1.6) 27.6 (1.8) 23.1 (2.1) <0.001 
APOE-ε4 positive (%) 33 36 47 60 71 <0.001 
TIV (ml) 1403 (134) 1414 (125) 1423 (136) 1436 (132) 1416 (151) 0.2 
WMH volume (ml)       Median (IQR)  3.4 (4.8) 3.4 (4.4) 3.8 (6.1) 3.7 (8.1) 5.8 (9.0) 0.005a 
LogeWMH (ml) 1.3 (0.9) 1.3 (0.9) 1.4 (1.0) 1.4 (1.0) 1.7 (1.0) 0.002a 
CSF Aβ1-42 (pg/ml)b 












CSF t-tau (pg/ml) b 












CSF p-tau (pg/ml) b    
                                                   Median (IQR) 












History of hypertension (%) 49 47 50 45 52 0.8 



















BMI 27.4 (4.6) 28.4 (6.3) 28.2 (5.3) 27.4 (4.9) 26.2 (5.3) <0.001 
History of diabetes (%) 7 10 11 9 15 0.2 
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differences were only observed between groups in body mass index (BMI), with a lower BMI 
observed in the AD group. Summary CSF marker statistics for the subgroup with Elecsys CSF 
Aβ1-42 measures are shown in Supplementary Table 1. 
 
3.2 CSF biomarkers and WMH 
Table 2:  Regression model results for the relationship between WMH and CSF Aβ1-42, by group 
Estimates are percentage decrease in WMH volume per one SD change (1 SD = 78.3pg/ml) in Aβ1-42. The SD is the pooled within-group SD, 
calculated from a linear regression model that allowed for differences in mean levels of Aβ1-42 by group. 
Key: SMC, significant memory concern; EMCI, early mild cognitive impairment; LMCI, late mild cognitive impairment; AD, Alzheimer’s 
disease; TIV, total intracranial volume; WMH, white matter hyperintensities. 
 
 
Figure 1: Scatter plots showing the relationship between WMH and CSF Aβ1-42 in controls, significant memory 
concern (SMC), early mild cognitive impairment (EMCI), late mild cognitive impairment (LMCI), Alzheimer’s 
disease (AD) groups. WMH volume is shown on a log scale and is unadjusted for any covariates.  
 
Table 2 shows the estimated percentage decreases in WMH for increases in CSF Aβ1-42 after 
adjustment for TIV and Figure 1 shows the corresponding scatter plots. Although the estimated 
slope of the association in the five diagnostic groups varied somewhat (and was not formally 
statistically significant in the LMCI group), 95% confidence intervals were relatively wide and the 
variability in estimates was consistent with chance (joint tests for differences in slopes among 
WMH and Aβ1-42 Controls SMC EMCI LMCI AD 
TIV adjusted 
% reduction in WMH (ml) per 1SD change in Aβ1-42            
95% confidence intervals                        
 p value    
                                 
30.4                     
(20.3 to 39.3) 
<0.001 
                             
20.0                    
(6.4 to 31.6)               
0.006 
                                
22.0                     
(12.5 to 30.5) 
<0.001 
                             
14.9                    
(-0.5 to 28.0)  
0.06 
                               
18.0                    
(-0.2 to 32.8)               
0.05 
TIV and age adjusted 
% reduction in WMH (ml) per 1SD change in Aβ1-42            
95% confidence intervals                        
 p value    
                                 
26.7                     
(15.7 to 36.2) 
<0.001 
                             
18.7                    
(5.2 to 30.2)    
0.009 
                               
12.3                     
(2.5 to 21.0)       
0.02 
                              
9.4                     
(-5.5 to 22.2)   
0.2 
                               
21.7                  
(6.8 to 34.2)               
0.006 
Between group differences in % reductions per 1SD change in Aβ1-42             p value = 0.4 (0.4 with age adjustment) 
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groups were not statistically significant). The effect of CSF Aβ1-42 on WMH was typically 
reduced after adjustment for age, but we did not find any material changes in effects after 
adjustment for gender (Supplementary Table 2). Supplementary Table 3 shows equivalent results 
to Table 2 using the Elecsys CSF Aβ1-42 assay. These results demonstrate similar findings using 
this alternative assay.  
 
Table 3:  Regression model results for the relationship between WMH and CSF t-tau, by group 
Estimates are percentage increase in WMH volume per one SD change (1 SD = 42.8pg/ml) in t-tau. The SD is the pooled within-group SD, 
calculated from a linear regression model that allowed for differences in mean levels of t-tau by group. 
Key: SMC, significant memory concern; EMCI, early mild cognitive impairment; LMCI, late mild cognitive impairment; AD, Alzheimer’s 





Figure 2: Scatter plots showing the relationship between WMH and CSF t-tau in controls, significant memory 
concern (SMC), early mild cognitive impairment (EMCI), late mild cognitive impairment (LMCI) and Alzheimer’s 
disease (AD) groups. WMH volume is shown on a log scale and is unadjusted for any covariates. 
 
Table 3 shows the percentage increases in WMH for increases in CSF t-tau and Figure 2 shows 
the corresponding scatter plots. With adjustment for TIV, WMH burden was borderline positively 
WMH and t-tau Controls SMC EMCI LMCI AD 
TIV adjusted 
% increase in WMH (ml) per 1SD change in t-tau            
95% confidence intervals                        
 p value    
                                 
5.1                     
(-16.4 to 32.0) 
0.7 
                            
3.8                    
(-24.9 to 43.5)               
0.8 
                               
13.2                     
(0.2 to 27.7) 
0.05 
                             
-4.0                    
(-16.9 to 11.1)  
0.6 
                              
-3.3                    
(-15.2 to 10.2)               
0.6 
TIV and age adjusted 
% increase in WMH (ml) per 1SD change in t-tau            
95% confidence intervals                        
 p value    
                                 
-7.3                     
(-26.2 to 16.3) 
0.5 
                            
-5.1                    
(-31.2 to 30.9)    
0.8 
                              
2.4                     
(-8.0 to 14.0)       
0.7 
                              
-3.9                     
(-15.7 to 9.5)   
0.6 
                              
3.6                  
(-7.9 to 16.5)               
0.6 
Between group differences in % increases per 1SD change in t-tau             p value = 0.4 (0.7 with age adjustment)  
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associated with t-tau only in the EMCI group. This association was no longer significant after 
adjusting for age. There was no evidence for an interaction between t-tau and group. 
 
Table 4:  Regression model results for the relationship between WMH and CSF p-tau, by group 
Estimates are percentage increase in WMH volume per one SD (1SD = 12.8pg/ml) change in p-tau. The SD is the pooled within-group SD, 
calculated from a linear regression model that allowed for differences in mean levels of p-tau by group. 
Key: SMC, significant memory concern; EMCI, early mild cognitive impairment; LMCI, late mild cognitive impairment; AD, Alzheimer’s 




Figure 3: Scatter plots showing the relationship between WMH and CSF p-tau in controls, significant memory 
concern (SMC), early mild cognitive impairment (EMCI), late mild cognitive impairment (LMCI), Alzheimer’s 
disease (AD) groups. WMH volume is shown on a log scale and is unadjusted for any covariates. 
 
Table 4 shows the percentage increases in WMH for increases in CSF p-tau and Figure 3 shows 
the corresponding scatter plots. There was no evidence for an association between WMH and p-





WMH and p-tau Controls SMC EMCI LMCI AD 
TIV adjusted 
% increase in WMH (ml) per 1SD change in p-tau            
95% confidence intervals                        
p value 
 
13.6                     
(-6.6 to 38.3) 
0.2 
 
14.1                    
(-8.8 to 42.8)               
0.3 
 
3.5                     
(-10.0 to 18.9) 
0.6 
 
-8.7                    
(-21.3 to 5.9)  
0.2 
 
0.5                    
(-10.8 to 13.3)               
0.9 
TIV and age adjusted 
% increase in WMH (ml) per 1SD change in p-tau            
95% confidence intervals                        
 p value    
                                 
7.3                     
(-11.3 to 29.9) 
0.5 
                            
13.1                    
(-9.0 to 40.5)    
0.3 
                              
-3.9                     
(-14.8 to 8.4)       
0.5 
                              
-3.0                     
(-15.3 to 11.1)   
0.7 
                              
8.0                  
(-3.0 to 20.3)               
0.1 
Between group differences in % increases per 1SD change in p-tau             p value = 0.4 (0.5 with age adjustment)  
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3.3 Relationships of CSF Aβ1-42 with WMH 
































































All models assess associations between WMH and Aβ1-42 with various covariates, with model 2 additionally adjusting for t-tau and model 3 
additionally adjusting for p-tau. In a) estimates are percentage changes in WMH volume per one SD change (1 SD = 78.3pg/ml) in Aβ1-42. The 
SD is the pooled within-group SD, calculated from a linear regression model that allowed for differences in mean levels of Aβ1-42 by group. In 
b) partial R2 are shown for each covariate in the fully-adjusted model v) from each of the three model sets. R2 values are shown to 2 significant 
figures for values >0.1 and 1 significant figure for values <0.1. 
Key: TIV, total intracranial volume; WMH, white matter hyperintensities 
 
a)      
Model set Covariates 
% reduction in WMH per 1SD 






i) None 21.9 17.1 to 26.5 <0.001 
ii) TIV 21.5 16.7 to 26.0 <0.001 
iii) TIV, group 21.6 16.2 to 26.6 <0.001 
iv) TIV, group, age 16.4 11.2 to 21.3 <0.001 
v) TIV, group, age, APOE-4 status 17.9 12.2 to 23.2 <0.001 
2 
i) T-tau 24.5 19.2 to 29.5 <0.001 
ii) T-tau, TIV 23.2 17.9 to 28.1 <0.001 
iii) T-tau, TIV, group 23.1 17.5 to 28.3 <0.001 
iv) T-tau, TIV, group, age 18.0 12.6 to 23.1 <0.001 
v) T-tau, TIV, group, age, APOE-4 status 18.8 13.0 to 24.2 <0.001 
3 
i) P-tau 24.1 18.7 to 29.1 <0.001 
ii) P-tau, TIV 23.8 18.6 to 28.7 <0.001 
iii) P-tau, TIV, group 23.8 18.2 to 29.0 <0.001 
iv) P-tau, TIV, group, age 17.7 12.2 to 23.0 <0.001 
v) P-Tau, TIV, group, age, APOE-4 status 18.9 12.9 to 24.4 <0.001 
b)   




















APOE-4 status 0.001 
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Table 5a shows the percentage reductions in WMH volume for a 1 SD increase in CSF Aβ1-42 
adjusting for group, age, APOE-4 status, t-tau and p-tau. The relationship between WMH and 
Aβ1-42 remains significant and materially unchanged (between a 16 and 22% reduction in 
WMH per 1SD change in Aβ1-42) after progressive adjustment for covariates. This association 
between CSF Aβ1-42 and WMH was also shown to be independent of the effects of CSF t-tau 
and p-tau.  
 
Table 5b shows partial R2 values for all the covariates in each model set. Aβ1-42 consistently 
uniquely explained approximately 5% of the variance in WMH across all models. Age explained 
the largest variance in WMH at ~15%, compared with tau biomarkers, group and APOE-4 status, 
with each only explaining only around 1%.  
 
Supplementary Table 4 shows analogous results to Table 5 using the Elecsys assay. The results 
are not materially changed by the use of this alternative CSF Aβ1-42 measurement. 
4. Discussion 
 
In this study, we found strong evidence for a consistent association between CSF Aβ1-42 and 
WMH in all diagnostic groups, whereby a decrease in CSF Aβ1-42 was associated with an increase 
in WMH, that was independent of CSF t-tau and independent of CSF p-tau. Furthermore, this 
relationship remained significant in the pooled cohort when adjusting for age, diagnostic group, 
TIV and APOE-4 status. There was very little evidence for a relationship between t-tau pathology 
and WMH, with a borderline positive association only in the EMCI group. No association of p-tau 
with WMH was observed. To our knowledge, this is the first study to look for a direct association 
between Aβ1-42 and tau CSF biomarkers and WMH volumes across the disease spectrum, from 
normal ageing to AD, including patients with EMCI and SMC. 
Our findings provide evidence for a link between WMH and amyloid pathology, from normal 
ageing through to clinical AD. Notably, evidence from autosomal dominantly inherited familial 
AD suggests that changes in WMH could occur in the presymptomatic stage of disease, deviating 
from normal controls around 6 years before symptom onset (Lee et al., 2016). Our observations 
from groups at higher risk of developing sporadic AD dementia add further weight to the notion 
that WMH are a core feature of AD. 
We did not find any evidence for differing relationships in WMH and Aβ1-42, p-tau or t-tau 
between diagnostic groups. WMH are heterogeneous and are likely to represent multiple 
pathologies that could potentially vary throughout the disease course. Given the recent evidence 
that WMH may be more related to neurodegenerative and tau pathologies in clinical AD 
(McAleese et al., 2017), it would have been reasonable to propose stronger relationships with tau 
at later disease stages. Since Aβ1-42 levels are thought to be relatively stable in clinical AD stages 
(Zhou et al., 2009), it could also be expected that there might be less of an association with WMH 
in later disease stages. The fact that we did not find any differences between disease stages suggests 
that WMH relationships with AD CSF biomarkers actually remain consistent across the disease 
course.   
Age at baseline was a stronger independent predictor of WMH than Aβ1-42, which likely reflects 
the contributions of vascular risk factors, vascular events, and co-morbidities that accrue with age. 
Taken together, although our study is purely correlative, our results are compatible with the theory 
that some WMH are part of the AD pathological process, and some are the result of an 
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ageing/vascular process (McAleese et al., 2015, McAleese et al., 2017). Although we did not find 
any evidence for contributions from smoking, hypertension, BMI and diabetes to the relationship 
between WMH and age (Supplementary Table 5), a more comprehensive examination of the 
effects of vascular risk factors, vascular disease and vascular related events on the age-WMH 
relationship may provide greater insight into the potential causes of WMH associated with age. 
In studies of Aβ and WMH there have been mixed findings; some have reported a lack of any 
association (Kalheim et al., 2017, Kester et al., 2014), whilst several studies confirm our findings 
that lower CSF Aβ1-42 is associated with higher WMH in both controls and disease groups 
(Marnane et al., 2016, Pietroboni et al., 2018). Some have reported that lower levels of CSF Aβ1-
42 were particularly associated with WMH in AD subjects, as opposed to controls or MCI subjects 
(Shams et al., 2016, Van Westen et al., 2016). Results from amyloid PET studies have also 
demonstrated significant associations with WMH in controls (Kandel et al., 2016, Marnane et al., 
2016), MCI and AD groups (Zhou et al., 2015). Although a recent systematic review concluded 
that most studies demonstrate a lack of significant relationship between amyloid PET and WMH 
burden (Roseborough et al., 2017). 
This study adds to the expanding body of literature attempting to characterise the complex 
relationship between AD and presumed vascular pathology at different disease stages. As well as 
evidence that both Aβ deposition and WMH independently predict cognitive impairment or brain 
atrophy (Barnes et al., 2013, Gordon et al., 2015, Haight et al., 2013, Provenzano et al., 2013), a 
growing number of studies are suggestive of an additive effect of combined pathology on 
neurodegeneration (Bos et al., 2018) and/or cognitive decline (Lopez et al., 2014, Vemuri and 
Knopman, 2016, Vemuri et al., 2015). Several studies have investigated the possibility of an 
interactive effect between the two pathologies, whereby there is a direct influence of one pathology 
on the other. One study found that WMH predicted hippocampal atrophy in preclinical AD subjects 
with abnormal CSF Aβ (Freeze et al., 2016), and another found that low CSF Aβ predicted greater 
WMH accrual over time (Scott et al., 2016). 
Hypotheses into mechanistic links between Aβ and WMH have mainly focused on the proposed 
vascular origin of WMH and reflect the idea that there may be positive feedback between the two 
pathologies (Smith and Greenberg, 2009, Zlokovic, 2011). Cerebral amyloid angiopathy (CAA) 
may be a potential mediator of the relationship between WMH and Aβ, whereby SVD could lead 
to reduced clearance of Aβ from brain parenchyma, enhancing its deposition in cerebral vessel 
walls. This in turn may result in cerebrovascular dysfunction, leading to eventual hypoperfusion 
and ischaemia and subsequent white matter lesions that appear as WMH (Grinberg and Thal, 2010, 
Hawkes et al., 2014, Weller et al., 2008). Previous research has demonstrated associations of CAA 
with WMH (Ryan et al., 2015) and with CSF Aβ (Renard et al., 2012, Verbeek et al., 2009). A 
recent paper has shown that WMH related to Aβ are associated with cerebral microbleeds (a 
surrogate of CAA pathology) (Graff-Radford et al., 2019). In addition to the vascular origin of 
WMH, recent evidence suggests that parietal WMH could be a result of degenerative axonal loss 
caused by AD pathology (McAleese et al., 2015, McAleese et al., 2017). In this study though, we 
did not find any evidence for a stronger association between CSF biomarkers and WMH in the 
parietal lobe (Supplementary Table 6).  
There are comparatively fewer studies regarding the association with tau and WMH and results 
are often conflicting. A positive association has been demonstrated neuropathologically 
(McAleese et al., 2015) and with PET (Vemuri et al., 2017); more direct measures of brain tau 
load than CSF measures. A positive association has been demonstrated over time in CSF, but the 
relationship is less clear with baseline measures of tau (Tosto et al., 2015). Our study did not find 
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much evidence of a relationship between tau pathology and WMH, which is in line with several 
other studies (Guzman et al., 2013, Kester et al., 2014, Osborn et al., 2018).  
The fact that age was the strongest predictor of WMH is consistent with previous studies (de Leeuw 
et al., 2001, Raz et al., 2012, Schneider et al., 2009). We also found that the association between 
biomarkers and age was not uniform between diagnostic groups (Supplementary Table 7). In 
controls and EMCI groups, older ages were associated with lower Aβ1-42 and higher tau, but in 
the AD group, younger ages were associated with higher tau. This differential effect of age on CSF 
biomarkers between AD groups and controls has been previously reported (Mattsson et al., 2012).  
Investigations of the associations between AD CSF biomarkers and WMH in previous studies have 
either been performed on small samples or in studies with variable acquisition and analysis 
protocols. (Bos et al., 2018, Freeze et al., 2016, Kalheim et al., 2017, Pietroboni et al., 2018, Tosto 
et al., 2015). Using the ADNI cohort therefore provides the benefits of a multi-centre standardised 
data acquisition protocol, as well as participants who have been systematically evaluated. Our 
study adds to previous findings using the ADNI cohort (Marnane et al., 2016, Scott et al., 2016, 
Haight et al., 2013, Guzman et al., 2013), in that data from all diagnostic groups are used and 
biomarkers for both tau and Aβ are compared with quantitative WMH. We also treated both our 
biomarker and WMH data as continuous variables; most previous studies have dichotomised 
variables. 
 
There are several limitations to this work, which include the selection criteria for the ADNI cohort 
meaning any generalisations to the wider population must be made cautiously. ADNI participants 
tend to be of high socioeconomic status, well-educated and, importantly for this study, free of large 
amounts of cerebrovascular disease (a score of 4 or lower on the Hachinski Ischemic 
Scale)(https://adni.loni.usc.edu/wp-content/uploads/2008/07/adni2-procedures-manual.pdf). This 
study was also only carried out using baseline data; longitudinal studies are necessary to 
characterise the relationship between WMH and AD biomarkers over time, an approach which 
will be facilitated by the increasing use of volumetric FLAIR imaging providing more precise 
measures of change. 
There are limitations surrounding the use of CSF biomarkers in this study to investigate AD 
pathology. CSF biomarkers can now be measured by several different assays, introducing the 
possibility that these methodological differences may influence study findings. However, 
Supplementary Tables 3 and 4 demonstrate that analyses carried out using another assay platform, 
Elecsys, confirm our findings of the associations between CSF biomarkers and WMH. 
Additionally, despite the benefits of using continuous biomarker variables, it would be interesting 
to look at associations within biomarker-negative and biomarker-positive individuals to explore 
whether associations may be driven by those on the amyloid pathway (Jack et al., 2018) or those 
who are not. CSF biomarkers are increasingly used to provide information about underlying 
biochemical changes associated with disease, with Aβ1-42 and p-tau well established as markers 
of AD pathology and t-tau as an established marker of neurodegeneration (Blennow et al., 2010, 
Jack et al., 2018). However, measures of actual brain Aβ and tau burden and their local distribution, 
through PET imaging or pathological investigations, were either not available or not used.  
This study only examined associations between WMH and the well-established AD biomarkers of 
CSF Aβ1-42, t-tau and p-tau. The existence of additional co-pathologies in AD suggest that further 
biomarkers are needed to complement these classical measurements. One biomarker of particular 
relevance is neurofilament light (NFL), a marker of large calibre axonal injury (Skillback et al., 
2014). Previous studies of associations between WMH and NFL have reported mixed results 
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(Mattsson et al., 2019, Osborn et al., 2018, Zetterberg et al., 2016), and therefore future analysis 
across the full spectrum of the disease course using our well-characterised WMH segmentation 
tool would be highly pertinent.   
A lack of pathological confirmation of cases in the ADNI cohort may, in part, explain our findings. 
Diagnostic groups may be bimodal in nature; control groups may contain atypical or early stage 
AD subjects along with the cognitively normal, and a significant proportion of MCI subjects 
supposedly at high risk for conversion to AD will not have any underlying AD pathology (Jicha et 
al., 2006, Petersen et al., 2006). Indeed in our study, this may have been a contributing factor to 
the lack of observed differences in biomarker and WMH relationships between diagnostic groups. 
Additionally, although the four measures of vascular risk used in this study are unlikely to fully 
characterise all aspects of SVD, they are among the most notable risk factors, as well as being the 
most consistently documented for the ADNI cohort.  
5. Conclusion 
 
In summary, our study suggests that CSF Aβ1-42 is a consistent predictor of WMH across all 
diagnostic groups, in a manner that is not dependent on CSF tau. As WMH are thought to be 
largely vascular in origin, this study adds to the literature exploring the complex relationship 
between amyloid and presumed vascular pathologies. Understanding the different relationships 
between disease markers are important to build more realistic models of biomarkers changes across 
the full spectrum of normal ageing to AD. 
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